Revolution Medicines (NASDAQ:RVMD – Get Rating) released its earnings results on Monday. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.04, MarketWatch Earnings reports. Revolution Medicines had a negative net margin of 636.58% and a negative return on equity of 28.26%. During the same quarter in the previous year, the company posted ($0.53) earnings per share.
Shares of RVMD stock opened at $14.99 on Tuesday. The firm has a fifty day moving average of $22.00 and a 200-day moving average of $24.25. Revolution Medicines has a 52-week low of $14.46 and a 52-week high of $35.07. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -5.86 and a beta of 2.01.
In other news, Director Thilo Schroeder bought 42,000 shares of the stock in a transaction dated Friday, March 25th. The shares were acquired at an average price of $24.79 per share, with a total value of $1,041,180.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders bought 972,079 shares of company stock worth $18,310,981. 22.60% of the stock is owned by insiders.
Several equities analysts recently commented on RVMD shares. Stifel Nicolaus upgraded shares of Revolution Medicines from a “hold” rating to a “buy” rating and cut their target price for the company from $36.00 to $26.00 in a research note on Tuesday, March 1st. Zacks Investment Research upgraded shares of Revolution Medicines from a “sell” rating to a “hold” rating in a research note on Saturday, April 23rd. Finally, HC Wainwright increased their price objective on shares of Revolution Medicines from $38.00 to $40.00 in a research note on Tuesday, March 1st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.00.
About Revolution Medicines (Get Rating)
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
- Get a free copy of the StockNews.com research report on Revolution Medicines (RVMD)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Intuitive Surgical is an Intuitive Buy
- The Low In Lordstown Motors May Not Be The Last
- Follow The Money To Cigna
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.